1. Elevated soluble receptor for advanced glycation end product levels in patients with acute coronary syndrome and positive cardiac troponin I
- Author
-
Debora Battaglia, Federica Marchi, Serena Del Turco, Teresa Navarra, Annamaria Mazzone, Sergio Berti, Antonella Mercuri, and Giuseppina Basta
- Subjects
Male ,Acute coronary syndrome ,medicine.medical_specialty ,Cardiac troponin ,Receptor for Advanced Glycation End Products ,Enzyme-Linked Immunosorbent Assay ,Coronary Angiography ,chemistry.chemical_compound ,Glycation ,Predictive Value of Tests ,Internal medicine ,Troponin I ,Medicine ,Humans ,In patient ,Angina, Stable ,Acute Coronary Syndrome ,Receptors, Immunologic ,Receptor ,Aged ,Chi-Square Distribution ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Up-Regulation ,Cross-Sectional Studies ,chemistry ,Italy ,Myocardial cell ,Cardiology ,Advanced glycation end-product ,Female ,Cardiology and Cardiovascular Medicine ,business ,Biomarkers - Abstract
Objectives High levels of soluble receptor for advanced glycation end products (sRAGE) have been shown to have an atheroprotective role; however, no data are available on this molecule in acute coronary syndromes (ACS). We evaluated sRAGE levels in patients with non-ST segment elevation ACS (NSTE-ACS) or with chronic stable angina. Methods We studied 265 patients, 190 of whom had NSTE-ACS and 75 had chronic stable angina. Results Plasma sRAGE values were comparable in the two groups (P=0.19). However, in the patients with NSTE-ACS, sRAGE levels were significantly higher in patients with cardiac troponin-I (cTnI) of more than or equal to 0.04 µg/l compared with those with cTnI of less than 0.04 µg/l [758 (493–1536 ) pg/ml vs. 454 (167–899) pg/ml; P=0.0037]. A significant correlation (r=0.323, P=0.0045) was found between sRAGE and cTnI levels in patients with NSTE-ACS. Conclusion Plasma sRAGE levels are elevated in patients with NSTE-ACS with positive cTnI, suggesting that they could be related to myocardial cell damage.
- Published
- 2011